Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives

被引:227
作者
Derendorf, H [1 ]
Meibohm, B
机构
[1] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
[2] Univ S Carolina, Coll Pharm, Dept Basic Pharmaceut Sci, Columbia, SC 29208 USA
关键词
pharmacokinetics; pharmacodynamics; pharmacology; modeling;
D O I
10.1023/A:1011907920641
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Pharmacokinetic/pharmacodynamic (PK/PD)-modeling links dose-concentration relationships (PK) and concentration-effect relationships (PD), thereby facilitating the description and prediction of the time course of drug effects resulting from a certain dosing regimen. PK/PD-modeling approaches can basically be distinguished by four major attributes. The first characterizes the link between measured drug concentration and the response system, direct link versus indirect link. The second considers how the response system relates effect site concentration to the observed outcome, direct versus indirect response. The third regards what clinically or experimentally assessed information is used to establish the link between concentration and effect, hard link versus soft link. And the fourth considers the time dependency of pharmacodynamic model parameters, distinguishing between time-variant versus time-invariant. Application of PK/PD-modeling concepts has been identified as potentially beneficial in all phases of preclinical and clinical drug development. Although today predominantly limited to research, broader application of PK/PD-concepts in clinical therapy will provide a more rational basis for patient-specific dosage individualization and may thus guide applied pharmacotherapy to a higher level of performance.
引用
收藏
页码:176 / 185
页数:10
相关论文
共 66 条
[1]   ACUTE TOLERANCE TO PRESSOR EFFECTS OF COCAINE IN HUMANS [J].
AMBRE, JJ .
THERAPEUTIC DRUG MONITORING, 1993, 15 (06) :537-540
[2]   Diclofenac plasma protein binding: PK-PD modelling in cardiac patients submitted to cardiopulmonary bypass [J].
Auler, JO ;
Espada, EB ;
Crivelli, E ;
Quintavalle, TBG ;
Kurata, A ;
Stolf, NAG ;
Issy, AM ;
Paschoa, OED ;
Danhof, M ;
Breimer, DD ;
Chamone, DAF ;
Santos, SRCJ .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 1997, 30 (03) :369-374
[3]   PHARMACODYNAMIC MODELS OF NITROGLYCERIN-INDUCED HEMODYNAMIC TOLERANCE IN EXPERIMENTAL HEART-FAILURE [J].
BAUER, JA ;
FUNG, HL .
PHARMACEUTICAL RESEARCH, 1994, 11 (06) :816-823
[4]   Efficacy measures: Surrogates or clinical outcomes? [J].
Blue, JW ;
Colburn, WA .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (09) :767-770
[5]   Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development - The 'Wooden Shoe' paradigm [J].
Breimer, DD ;
Danhof, M .
CLINICAL PHARMACOKINETICS, 1997, 32 (04) :259-267
[6]   STEREOCHEMICAL ASPECTS OF WARFARIN DRUG-INTERACTIONS - USE OF A COMBINED PHARMACOKINETIC-PHARMACODYNAMIC MODEL [J].
CHAN, E ;
MCLACHLAN, A ;
OREILLY, R ;
ROWLAND, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (03) :286-294
[7]   KINETICS OF COCAINE DISTRIBUTION, ELIMINATION, AND CHRONOTROPIC EFFECTS [J].
CHOW, MJ ;
AMBRE, JJ ;
RUO, TI ;
ATKINSON, AJ ;
BOWSHER, DJ ;
FISCHMAN, MW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (03) :318-324
[8]   PHARMACOKINETIC PHARMACODYNAMIC MODELING - WHAT IT IS [J].
COLBURN, WA .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1987, 15 (05) :545-553
[9]   SIMULTANEOUS PHARMACOKINETIC AND PHARMACODYNAMIC MODELING [J].
COLBURN, WA .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1981, 9 (03) :367-388
[10]   Selecting and validating biologic markers for drug development [J].
Colburn, WA .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (05) :355-362